BRPI1010718A2 - sistemas modelo e regimes de tratamento para tratar doença neurológica. - Google Patents

sistemas modelo e regimes de tratamento para tratar doença neurológica.

Info

Publication number
BRPI1010718A2
BRPI1010718A2 BRPI1010718A BRPI1010718A BRPI1010718A2 BR PI1010718 A2 BRPI1010718 A2 BR PI1010718A2 BR PI1010718 A BRPI1010718 A BR PI1010718A BR PI1010718 A BRPI1010718 A BR PI1010718A BR PI1010718 A2 BRPI1010718 A2 BR PI1010718A2
Authority
BR
Brazil
Prior art keywords
treatment regimens
neurological disease
model systems
treat neurological
treat
Prior art date
Application number
BRPI1010718A
Other languages
English (en)
Inventor
Jonathan David Garman
Michael Tymianski
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of BRPI1010718A2 publication Critical patent/BRPI1010718A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
BRPI1010718A 2009-06-10 2010-06-10 sistemas modelo e regimes de tratamento para tratar doença neurológica. BRPI1010718A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10
PCT/US2010/038200 WO2010144721A2 (en) 2009-06-10 2010-06-10 Model systems and treatment regimes for treatment of neurological disease

Publications (1)

Publication Number Publication Date
BRPI1010718A2 true BRPI1010718A2 (pt) 2016-03-15

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010718A BRPI1010718A2 (pt) 2009-06-10 2010-06-10 sistemas modelo e regimes de tratamento para tratar doença neurológica.

Country Status (14)

Country Link
US (2) US8940699B2 (pt)
EP (2) EP2440230B1 (pt)
JP (2) JP6005514B2 (pt)
CN (1) CN102458441A (pt)
AU (1) AU2010258664B2 (pt)
BR (1) BRPI1010718A2 (pt)
CA (1) CA2765169C (pt)
DK (1) DK2440230T3 (pt)
ES (1) ES2847293T3 (pt)
HR (1) HRP20210112T1 (pt)
HU (1) HUE053131T2 (pt)
PL (1) PL2440230T3 (pt)
PT (1) PT2440230T (pt)
WO (1) WO2010144721A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CN102458441A (zh) 2009-06-10 2012-05-16 诺诺公司 用于治疗神经疾病的模型系统和治疗方案
CA2807946C (en) 2010-08-12 2018-09-25 Nono Inc. Treatment of penetrative injury to the brain
DK2723363T3 (en) 2011-06-24 2018-10-15 Nono Inc COMBINATION THERAPY AGAINST CREAM
DK2800575T3 (da) * 2011-12-13 2019-07-01 Nono Inc Behandling af subarachnoidalblødning og iskæmi
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
EP2925338B8 (en) * 2012-11-28 2019-05-22 NoNO Inc. Lyophilized formulation of tat-nr2b9c
AU2015265487B2 (en) * 2014-05-28 2020-08-13 Nono Inc. Chloride salt of TAT-NR2B9c
US11229675B2 (en) 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
WO2017185250A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
BR112020000115A2 (pt) 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
BR112020006321A2 (pt) 2017-09-30 2020-11-17 Biocells (Beijing) Biotech Co., Ltd. composição de peptídeos para tratamento de lesões relacionadas a neurotoxicidade excitatória
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
CN113735938A (zh) 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114469084B (zh) * 2022-04-02 2022-06-24 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
EP1578365A4 (en) * 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
CA2524573A1 (en) 2003-05-02 2004-11-11 Paion Deutschland Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US8685925B2 (en) * 2006-07-11 2014-04-01 Nono Inc. Method and compositions for treating stroke with fever
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
CN102458441A (zh) 2009-06-10 2012-05-16 诺诺公司 用于治疗神经疾病的模型系统和治疗方案
DK2723363T3 (en) 2011-06-24 2018-10-15 Nono Inc COMBINATION THERAPY AGAINST CREAM
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
DK2800575T3 (da) 2011-12-13 2019-07-01 Nono Inc Behandling af subarachnoidalblødning og iskæmi

Also Published As

Publication number Publication date
JP6220371B2 (ja) 2017-10-25
EP3808366A1 (en) 2021-04-21
US8940699B2 (en) 2015-01-27
US9610323B2 (en) 2017-04-04
WO2010144721A2 (en) 2010-12-16
PT2440230T (pt) 2021-02-03
JP2016041731A (ja) 2016-03-31
WO2010144721A3 (en) 2011-04-21
US20150202253A1 (en) 2015-07-23
US20120269733A1 (en) 2012-10-25
DK2440230T3 (da) 2021-01-18
AU2010258664B2 (en) 2015-05-28
EP2440230B1 (en) 2020-11-11
EP2440230A2 (en) 2012-04-18
PL2440230T3 (pl) 2021-06-14
HUE053131T2 (hu) 2021-06-28
JP6005514B2 (ja) 2016-10-12
JP2012530057A (ja) 2012-11-29
EP2440230A4 (en) 2014-05-28
ES2847293T3 (es) 2021-08-02
CA2765169C (en) 2019-06-18
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
CN102458441A (zh) 2012-05-16
HRP20210112T1 (hr) 2021-04-16

Similar Documents

Publication Publication Date Title
BRPI1010718A2 (pt) sistemas modelo e regimes de tratamento para tratar doença neurológica.
CA145381S (en) Pet treat
CA145379S (en) Pet treat
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0915112A2 (pt) cateter de entalhe para tratar válvulas cardíacas doentes
BR112012008367A2 (pt) sistemas e métodos de tratamento de águas residuais.
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
BRPI1015233A2 (pt) métodos para tratar ou prevenir a fadiga
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
IT1400425B1 (it) Modified snrnas for use in therapy.
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
BRPI0919127A2 (pt) métodos para tratamento de água
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
CA145380S (en) Pet treat
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
IL214133A0 (en) Skin treatment
BR112013004683A2 (pt) "conjunto de cateter para tratamento de nervo"
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BR112012013591A2 (pt) dispositivo para tratamento eletroterapêutico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal